| SELLAS LIFE SCIENCES GRP |
| USA |
| Gesundheit |
| US81642T2096 / A2PU3T |
| RXK3 (Frankfurt) / SLS (NASDAQ) |
| FRA:RXK3, ETR:RXK3, RXK3:GR, NASDAQ:SLS |
| - |
| https://www.sellaslifesci.. |
|
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer. SELLAS Life Sciences Group, Inc. concentrates on immunotherapeutic and targeted oncology programs designed to addres..
>Volltext.. |
| 2080.33 Mio. EUR |
| 1959.6 Mio. EUR |
| - |
| -31.44 Mio. EUR |
| -28.98 Mio. EUR |
| -0.19 EUR |
| 0.66 Mio. EUR |
| 123.58 Mio. EUR |
| -25.37 Mio. EUR |
| 18.29 |
| - |
| -27.51% |
| - |
| - |
| - |
| - |
| SELLAS LIFE |
| 28.10.26 |
|
||||
|